Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Travere Therapeutics, Inc., IDEAYA Biosciences or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Travere Therapeutics, Inc., IDEAYA Biosciences and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Travere Therapeutics, Inc., IDEAYA Biosciences and Inc.

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company’s products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer driven by GNAQ/11 mutations, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor that is in a Phase 1 clinical trial for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 dose optimization trial; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Latest Biotechnology and Travere Therapeutics, Inc., IDEAYA Biosciences, Inc. Stock News

As of February 18, 2026, Travere Therapeutics, Inc. had a $2.5 billion market capitalization, compared to the Biotechnology median of $251.8 million. Travere Therapeutics, Inc.’s stock is down 25.6% in 2026, down 6% in the previous five trading days and up 21.65% in the past year.

Currently, Travere Therapeutics, Inc. does not have a price-earnings ratio. Travere Therapeutics, Inc.’s trailing 12-month revenue is $435.8 million with a -20.3% net profit margin. Year-over-year quarterly sales growth most recently was 162.2%. Analysts expect adjusted earnings to reach $0.894 per share for the current fiscal year. Travere Therapeutics, Inc. does not currently pay a dividend.

As of February 18, 2026, IDEAYA Biosciences, Inc. had a $2.7 billion market cap, putting it in the 59th percentile of all stocks. IDEAYA Biosciences, Inc.’s stock is down 6.9% in 2026, up 0.9% in the previous five trading days and up 47.24% in the past year.

Currently, IDEAYA Biosciences, Inc. does not have a price-earnings ratio. IDEAYA Biosciences, Inc.’s trailing 12-month revenue is $218.7 million with a -52.0% net profit margin. Year-over-year quarterly sales growth most recently was 55.7%. Analysts expect adjusted earnings to reach $-3.858 per share for the current fiscal year. IDEAYA Biosciences, Inc. does not currently pay a dividend.

How We Compare Travere Therapeutics, Inc., IDEAYA Biosciences and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Travere Therapeutics, Inc., IDEAYA Biosciences and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Travere Therapeutics, Inc., IDEAYA Biosciences and Inc. Growth Grades

Company	Ticker	Growth
Travere Therapeutics, Inc.	TVTX	D
IDEAYA Biosciences, Inc.	IDYA	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Travere Therapeutics, Inc. has a Growth Score of 36, which is Weak. IDEAYA Biosciences, Inc. has a Growth Score of 12, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither Travere Therapeutics, Inc., IDEAYA Biosciences or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Travere Therapeutics, Inc., IDEAYA Biosciences or Inc. is the better investment when it comes to sustainable growth.

Travere Therapeutics, Inc., IDEAYA Biosciences and Inc.’s Momentum Grades

Company	Ticker	Momentum
Travere Therapeutics, Inc.	TVTX	C
IDEAYA Biosciences, Inc.	IDYA	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Travere Therapeutics, Inc. has a Momentum Score of 60, which is Average. IDEAYA Biosciences, Inc. has a Momentum Score of 65, which is Strong.

The Momentum Grade Winner: IDEAYA Biosciences, Inc.

As you can clearly see from the Momentum Grade breakdown above, IDEAYA Biosciences, Inc. is considered to have stronger momentum compared to Travere Therapeutics, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, IDEAYA Biosciences, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Travere Therapeutics, Inc., IDEAYA Biosciences and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Travere Therapeutics, Inc.	TVTX	A
IDEAYA Biosciences, Inc.	IDYA	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Travere Therapeutics, Inc. has a Earnings Estimate Score of 85, which is Very Positive. IDEAYA Biosciences, Inc. has a Earnings Estimate Score of 31, which is Negative.

The Earnings Estimate Revisions Grade Winner: Travere Therapeutics, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Travere Therapeutics, Inc. has a better Earnings Estimate Revisions Grade than IDEAYA Biosciences, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Travere Therapeutics, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Travere Therapeutics, Inc., IDEAYA Biosciences and Inc. Grades

In addition to Momentum, Estimate Revisions and Growth, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Travere Therapeutics, Inc., IDEAYA Biosciences and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Travere Therapeutics, Inc., IDEAYA Biosciences or Inc. Stock?

Overall, Travere Therapeutics, Inc. stock has a Growth Score of 36, Momentum Score of 60 and Estimate Revisions Score of 85.

IDEAYA Biosciences, Inc. stock has a Growth Score of 12, Momentum Score of 65 and Estimate Revisions Score of 31.

Comparing Travere Therapeutics, Inc., IDEAYA Biosciences and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.